Dopamine D2 receptor imaging and neuroleptic drug response

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 11, 1996, Pages 84-88

  Heinz, Andreas ^a   Knable, Michael B ^a   Weinberger, Daniel R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

DOPAMINERGIC SYSTEM; DRUG RECEPTOR BINDING; DRUG RESPONSE; HUMAN; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR DENSITY; REVIEW; ARTICLE; BLOOD; BRAIN; CHEMICALLY INDUCED DISORDER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORPUS STRIATUM; DELAYED RELEASE FORMULATION; DRUG EFFECT; EXTRAPYRAMIDAL SYNDROME; METABOLISM; SCHIZOPHRENIA; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BRAIN; CORPUS STRIATUM; DELAYED-ACTION PREPARATIONS; HUMANS; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 0029861016     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Wong DF, Wagner HN, Tune LE, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986;231:1558-1563
2. Farde L, Wiesel F-A, Stone-Elander S, et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. Arch Gen Psychiatry 1990;47:213-219
3. 76Br]bromospiperone in untreated schizophrenic patients. Am J Psychiatry 1990; 147:44-50
4. Hietala J, Syvalahti E, Vuorio K, et al. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 1994;51:116-123
5. 123I-IBZM single photon emission computerised tomography study. Br J Psychiatry 1994;164:16-26
6. Nordstrom AL, Farde L, Eriksson L, et al. Noelevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and 11C N-methylspiperone. Psychiatry Res: Neuroimaging 1995;61:67-83
7. Wolkin A, Brodie JD, Barouche F, et al. Dopamine receptor occupancy and plasma haloperidol levels. Arch Gen Psychiatry 1989;46:482-483
8. Farde F, Wiesel FA, Halldin C, et al. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsycholic drugs. Arch Gen Psychiatry 1988;45:71-76
9. Nyberg S, Farde L, Halldin C, et al. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995; 152:173-178
10. Brücke T, Podreka I, Angelberger P, et al. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatrie disorders. J Cereb Blood Flow Metab 1991;11:220-228
11. Scherer J, Tatsch K, Schwartz J, et al. Striatal D2-dopamine receptor occupancy during treatment with typical and atypical neuroleptics. Biol Psychiatry 1994;36:627-629
12. Klemm E, Grunwald F, Kasper S, et al. 123 I-IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. Am J Psychiatry 1996;153:183-190
13. Brücke T, Roth J, Podreka I, et al. Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics [letter]. Lancet 1992;339:497
14. Pickar D, Su T-P, Weinberger DR, et al. Individual variation in D2 occupancy in clozapine treated patients. Am J Psychiatry. In press
15. 2 occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995;152:1444-1449
16. Nordström A-L, Farde L, Wiesel F-A, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-235
17. Kapur S, Remington G, Jones C, et al. High levels of dopamine D2 receptor occupancy with low dose haloperidol treatment: a PET study. Am J Psychiatry 1996;153:948-950
18. Coppens HJ, Sloof CJ, Paans AM, et al. High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients. Biol Psychiatry 1991;26:629-634
19. Geany DP, Ellis PM, Soper N, et al. Single emission tomography assessment of cerebral dopamine D2 receptor blockade in schizophrenia. Biol Psychiatry 1992;32:293-295
20. Pilowsky LS, Costa DC, Ell PJ, et al. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992;340:199-202
21. 123I IBZM SPET (single photon emission tomography) study. Psychol Med 1993;23:791-797
22. 123I-iodobenzamide in chronic schizophrenia. Psychiatry Res 1994;55:111-118
23. Wolkin A, Barouche F, Wolf AP, et al. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989;146:905-908
24. Nyberg S, Farde L, Erikson L, et al. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. Psychopharmacology (Berl) 1993;110: 265-272
25. Kapur S, Remington G, Zipursky RB, et al. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995;10:103-107
26. Farde L, Nordström A-L, Wiesel F-A, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-544
27. Pilowsky LS, Busatto GF, Taylor M, et al. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine: a 123 IIBZM single photon emission tomography (SPET) study. Psychopharmacology (Berl) 1996;124:148-153
28. Van Tol HHM, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610-614
29. Müller WE. Pharmacology of neuroleptics with special reference to remoxipride. Krankenhauspsychiatrie 1992;3:14-22
30. Scherer J, Tatsch K, Schwarz J, et al. D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects. Acta Psychiatr Scand 1994;90:266-268
31. Jellinger K. The pathology of Parkinson's disease. In: Marsden CD, Fahn S, eds. Movement Disorders. 2nd ed. London, England: Butterworths; 1987:124-165
32. Laux G. Pharmacokinetics and side effects of neuroleptics with special reference to benzamides. Krankenhauspsychiatrie 1992;3:23-27
33. Farde L, von Bahr C. Distribution of remoxipride to the human brain and central D2-receptor binding examined in vivo by PET. Acta Psychiatr Scand 1990;82(suppl 358):67-71
34. Devaud LL, Hollingsworth EB, Cooper BR. Alterations in extracellular and tissue levels of biogenic amines in rat brain induced by the serotonin2 receptor antagonist ritanserin. J Neurochem 1992;59:1459-1466
35. Gardner EL, Chen J, Paredes W. Clozapine produces potent anti-dopaminergic effects anatomically specific to the mesolimbic system. J Clin Psychiatry 1994;55(9. suppl B):15-22
36. Lipska BK, Weinberger DR. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophr Res 1995;16:87-110
37. Knable MB, Weinberger DR. Limbic-prefrontal connectivity and clozapine. J Clin Psychiatry 1994;55(9, suppl B):70-73
38. Farde L, Hall H, Pauli S, et al. Variability in D2-dopamine receptor density and affinity: a PET study with (11C) raclopride in man. Synapse 1995;20: 200-208
39. Seibyl JP, Woods SW, Zoghbi SS, et al. Dynamic SPECT imaging of dopamine D2 receptors in human subjects with iodine-123-IBZM. J Nucl Med 1992;33:1964-1971
40. Moghaddam B. Preferential activation of cortical dopamine neurotransmission by clozapine: functional significance. J Clin Psychiatry 1994;55(9, suppl B):27-29
41. Knable MB, Jones DW, Coppola R, et al. Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease. J Nucl Med 1995;36:1216-1225
42. Seibyl JP, Zea-Ponce Y, Brenner L, et al. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agenl RWJ-37796. J Nucl Med 1996;37:11-15